Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Patient is male between 21 and 55 years of age

• Duration of the illness must be longer than 1 year

• Patient's current antipsychotic medication regimen must be stable

• Patient is negative for selected drugs of abuse at Screening

• Must be in a stable living arrangement for at least 3 months prior to screening (not a homeless shelter)

Exclusion Criteria:

• Patient has mental retardation

• Undergone Electroconvulsive Therapy (ECT) treatment within 6 months prior to screening

• Has suicidal attempts or ideation within the last 12 months

• Patient has a history of alcohol/drug dependence within 1 year or alcohol/drug abuse within 12 months of starting the study